A mitochondrial permeability transition pore inhibitor improves renal outcomes after revascularization in experimental atherosclerotic renal artery stenosis.

@article{Eirin2012AMP,
  title={A mitochondrial permeability transition pore inhibitor improves renal outcomes after revascularization in experimental atherosclerotic renal artery stenosis.},
  author={Alfonso Eirin and Zilun Li and Xin Zhang and James D. Krier and John R. Woollard and Xiang-yang Zhu and Hui Tang and Sandra M.S. Herrmann and Amir Lerman and Stephen C. Textor and Lilach Orly Lerman},
  journal={Hypertension},
  year={2012},
  volume={60 5},
  pages={1242-9}
}
Revascularization improves blood pressure but not renal function in most patients with atherosclerotic renal artery stenosis (ARAS), possibly related to injury incurred during renal reperfusion. Bendavia, a novel tetrapeptide that inhibits mitochondrial permeability transition pore opening, reduces apoptosis, oxidative stress, and ischemia-reperfusion injury in experimental models. However, its potential for improving renal response to revascularization of chronic ARAS is unknown. We… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

Role of 2',3'-cyclic nucleotide 3'-phosphodiesterase in the renal 2',3'-cAMP-adenosine pathway.

American journal of physiology. Renal physiology • 2014
View 8 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Mitochondrial biogenesis in kidney disease.

Journal of the American Society of Nephrology : JASN • 2011

Similar Papers

Loading similar papers…